Funded Biotechnology Startups in United Kingdom
The 50 most recent funding rounds in UK biotechnology span December 2024 through November 2025, covering stages from Pre-Seed to Series D and geographies f…
The 50 most recent funding rounds in UK biotechnology span December 2024 through November 2025, covering stages from Pre-Seed to Series D and geographies from Belfast to Falkirk. Cambridge and London together account for roughly half the companies shown: Cambridge names include Artios Pharma ($115M Series D, November 2025), CellCentric ($120M Series C, May 2025), NRG Therapeutics ($68M Series B, September 2025), and Sortera Bio ($10M Pre-Seed, June 2025); London includes Verdiva Bio ($411M Series A, January 2025), Alchemab Therapeutics ($32M Series A, September 2025), and Epoch Biodesign ($18M Series A, March 2025).
A large share of rounds carry "Series Unknown" designations or undisclosed amounts — a pattern visible across companies at multiple stages. Seed activity extends well beyond the two main hubs: InvenireX (Newcastle, $3M, November 2025), Forge Genetics (Nottingham, $3M, October 2025), and Concinnity Genetics (Edinburgh, $4M, December 2024) each closed Seed rounds within the period shown.
Most recent rounds
50 shownRelated listings
Frequently asked
What are the largest disclosed funding rounds in this dataset?
Verdiva Bio closed a $411M Series A in London in January 2025, the largest disclosed round in the data by a wide margin. COMPASS Pathways ($150M, January 2025), CellCentric ($120M Series C, May 2025), and Artios Pharma ($115M Series D, November 2025) follow. NRG Therapeutics raised $68M in a Series B in Cambridge in September 2025.
Which UK cities have the most biotech funding activity?
Cambridge and London are the dominant hubs. Around ten of the fifty companies are Cambridge-based — including Artios Pharma, CellCentric, NRG Therapeutics, PACT, Sortera Bio, and Abselion — while roughly fourteen are London-based, including Verdiva Bio, Alchemab Therapeutics, and Epoch Biodesign. Newcastle, Edinburgh, and Belfast each appear three or more times among the remaining companies.
What funding stages are most common among UK biotech companies here?
"Series Unknown" is the most frequent classification in the dataset, often reflecting undisclosed or non-standard structures. Seed is the most common labeled stage, with nine companies at that level spanning London, Newcastle, Nottingham, and Edinburgh. Nine additional rounds carry Series A through D designations; Pre-Seed appears twice.
Are there any unusually large early-stage rounds in this group?
Sortera Bio (Cambridge) raised $10M at Pre-Seed in June 2025, which is atypically large for that stage. Level Zero Health raised $7M at Pre-Seed in London in February 2025. Verdiva Bio's $411M Series A in January 2025 is also outsized by any standard for a labeled Series A round.
Which companies raised Series B or above?
Four companies in the dataset reached Series B or above: NRG Therapeutics (Series B, $68M, Cambridge), OXCCU (Series B, $28M, Oxford), CellCentric (Series C, $120M, Cambridge), and Artios Pharma (Series D, $115M, Cambridge). Three of the four are Cambridge-based, and all four disclosed their round amounts.
How broad is the geographic spread of funded UK biotech outside London and Cambridge?
Newcastle has five companies represented — InvenireX, GlycanAge, Aelius Biotech, Atelerix, and Newcells Biotech. Edinburgh contributes EnteroBiotix, Dyneval, and Concinnity Genetics; Belfast contributes Neurovalens, Dia Beta Labs, and Diaceutics. Single companies appear in Nottingham, Oxford, Birmingham, Manchester, Falkirk, Glasgow, and Bath, indicating activity across England, Scotland, and Northern Ireland.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.